<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="pmc-domain-id">2604</journal-id><journal-id journal-id-type="pmc-domain">ofid</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12163371</article-id><article-id pub-id-type="pmcid-ver">PMC12163371.1</article-id><article-id pub-id-type="pmcaid">12163371</article-id><article-id pub-id-type="pmcaiid">12163371</article-id><article-id pub-id-type="pmid">40519632</article-id><article-id pub-id-type="doi">10.1093/ofid/ofaf315</article-id><article-id pub-id-type="publisher-id">ofaf315</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Special Collection: Infectious Diseases in People Who Use Drugs</subject><subj-group subj-group-type="category-toc-heading"><subject>Behavioral and Social Aspects of Infectious Diseases</subject></subj-group></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00290</subject></subj-group></article-categories><title-group><article-title>Impact of Substance Use Disorders on Outcomes of Medically Insured Persons Receiving Multiweek Outpatient Parenteral Antimicrobial Therapy: a Claims-based Cohort Study From 2015 to 2020</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-3968-6074</contrib-id><name name-style="western"><surname>Rogers</surname><given-names initials="DJ">Daniel J</given-names></name><aff>
<institution>Department of Pharmacy, Emory Healthcare</institution>, <addr-line>Atlanta, Georgia</addr-line>, <country country="US">USA</country></aff><xref rid="FM1" ref-type="author-notes"/><xref rid="ofaf315-cor1" ref-type="corresp"/><xref rid="FN01" ref-type="author-notes"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-7698-781X</contrib-id><name name-style="western"><surname>Zhao</surname><given-names initials="L">Lingyu</given-names></name><aff>
<institution>School of Economics and Management, University of Science and Technology Beijing</institution>, <addr-line>Beijing</addr-line>, <country country="CN">China</country></aff><aff>
<institution>Department of Statistics, UGA Franklin College of Arts and Sciences</institution>, <addr-line>Athens, Georgia</addr-line>, <country country="US">USA</country></aff><xref rid="FM2" ref-type="author-notes"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhan</surname><given-names initials="D">Duna</given-names></name><aff>
<institution>Department of Statistics, UGA Franklin College of Arts and Sciences</institution>, <addr-line>Athens, Georgia</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1806-0883</contrib-id><name name-style="western"><surname>Chen</surname><given-names initials="X">Xianyan</given-names></name><aff>
<institution>Department of Epidemiology &amp; Biostatistics, University of Georgia College of Public Health</institution>, <addr-line>Athens, Georgia</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1746-7462</contrib-id><name name-style="western"><surname>Krsak</surname><given-names initials="M">Martin</given-names></name><aff>
<institution>Division of Infectious Diseases, University of Colorado</institution>, <addr-line>Aurora, Colorado</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7363-8652</contrib-id><name name-style="western"><surname>Henao-Mart&#237;nez</surname><given-names initials="AF">Andr&#233;s F</given-names></name><aff>
<institution>Division of Infectious Diseases, University of Colorado</institution>, <addr-line>Aurora, Colorado</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4018-0195</contrib-id><name name-style="western"><surname>Chastain</surname><given-names initials="DB">Daniel B</given-names></name><aff>
<institution>Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy</institution>, <addr-line>Albany, Georgia</addr-line>, <country country="US">USA</country></aff><xref rid="ofaf315-cor1" ref-type="corresp"/><xref rid="FN01" ref-type="author-notes"/></contrib></contrib-group><author-notes><fn id="FM1"><p>Research was completed while enrolled in the Pharm.D. program at the University of Georgia College of Pharmacy, Athens, GA, 30602, USA.</p></fn><fn id="FM2"><p>Research was completed while enrolled in the Department of Statistics, UGA Franklin College of Arts and Sciences, Athens, GA, 30602, USA.</p></fn><corresp id="ofaf315-cor1">Correspondence: Daniel J. Rogers, Pharm.D., PGY-2 Infectious Diseases Pharmacy Resident, Department of Pharmacy, Emory Healthcare, 550 Peachtree St NE, Atlanta, GA 30308. (<email>daniel.rogers@emoryhealthcare.org</email>); Daniel B. Chastain, Pharm.D., BCIDP, AAHIVP, FIDSA, Department of Clinical and Administrative Pharmacy, Clinical Associate Professor, University of Georgia College of Pharmacy, 1000 Jefferson Street, Albany, GA 31701. (<email>daniel.chastain@uga.edu</email>).</corresp><fn id="FN01" fn-type="COI-statement"><p>
<bold>
<italic toggle="yes">Potential conflicts of interest.</italic>
</bold> All authors: No reported conflicts.</p></fn></author-notes><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-06-02"><day>02</day><month>6</month><year>2025</year></pub-date><volume>12</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">489629</issue-id><elocation-id>ofaf315</elocation-id><history><date date-type="received"><day>25</day><month>9</month><year>2024</year></date><date date-type="editorial-decision"><day>23</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>5</month><year>2025</year></date><date date-type="corrected-typeset"><day>13</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-26 04:25:24.337"><day>26</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#8212;for further information please contact journals.permissions@oup.com.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ofaf315.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ofaf315.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Outpatient parenteral antimicrobial therapy (OPAT) is often withheld from individuals with substance use disorder (SUD), despite evidence suggesting similar outcomes. We investigated this using a large, nationwide claims database.</p></sec><sec id="s2"><title>Methods</title><p>We analyzed Merative MarketScan (2015&#8211;2020) data to identify adults treated with intravenous vancomycin, daptomycin, nafcillin, oxacillin, or cefazolin for &#8805;7 days after hospitalization. Patients with end-stage renal disease or <italic toggle="yes">Clostridioides difficile</italic> were excluded. SUD was defined using pre-discharge International Classification of Diseases 10-CM codes. Rates of overdose, central venous catheter (CVC) events during OPAT, and 90-day all-cause readmissions following OPAT completion were compared between patients with and without SUD, adjusting for confounders via multivariable logistic regression.</p></sec><sec id="s3"><title>Results</title><p>Among 5903 patients, 18% had SUD. These patients were younger, less often male, and less likely discharged home. Unadjusted rates of 90-day readmission (40.1% vs 32.5%, <italic toggle="yes">P</italic> &lt; .001) and overdose (1.2% vs 0.1%, <italic toggle="yes">P</italic> &lt; .001) were higher in the SUD group, whereas CVC event rates were similar (6.5% vs 5.3%, <italic toggle="yes">P</italic> = .137). However, adjusted analyses revealed SUD was not significantly associated with readmission (odds ratio [OR] 1.16, <italic toggle="yes">P</italic> = .067) or CVC events (OR 1.10, <italic toggle="yes">P</italic> = .552), but was associated with higher odds of overdose (OR 6.03, <italic toggle="yes">P</italic> &lt; .001). Readmission was predicted by insurance type, mental health disorders, and infection type. CVC events were associated with infection type and discharge to home.</p></sec><sec id="s4"><title>Conclusions</title><p>SUD was not independently associated with increased 90-day readmission or CVC event risk, but was a significant risk factor for overdose, supporting harm reduction approaches over exclusion from OPAT based on SUD status.</p></sec></abstract><abstract abstract-type="teaser"><p>Substance use disorder was not significantly associated with 90-day readmission or central venous catheter events. However, insurance type, mental health disorders, and infection type influenced readmission risk. Additionally, patients with substance use disorder had significantly higher odds of overdose.</p></abstract><kwd-group><kwd>anti-bacterial agents</kwd><kwd>anti-infective agents</kwd><kwd>drug overdose</kwd><kwd>OPAT</kwd><kwd>substance-related disorders</kwd></kwd-group><counts><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Substance use disorder (SUD) is a prevalent public health crisis in the United States, affecting more than 1 in 6 individuals in 2023 [<xref rid="ofaf315-B1" ref-type="bibr">1</xref>]. Injection drug use, a potential manifestation of severe SUD, has dramatically increased, with a threefold rise between 2011 and 2018, impacting over 1 in 70 individuals [<xref rid="ofaf315-B2" ref-type="bibr">2</xref>]. This epidemic has been accompanied by a substantial rise in bacterial infections, including infective endocarditis and osteomyelitis, with nearly 40% and 20% of cases, respectively, occurring in individuals with SUD [<xref rid="ofaf315-B2" ref-type="bibr">2</xref>, <xref rid="ofaf315-B3" ref-type="bibr">3</xref>].</p><p>Injection drug use predisposes individuals to bloodstream infections, osteomyelitis, and infective endocarditis through direct inoculation of pathogens [<xref rid="ofaf315-B4" ref-type="bibr">4</xref>]. These infections are commonly, though not always, caused by Gram-positive bacteria and have traditionally required prolonged intravenous (IV) antibacterial therapy, often exceeding 4 to 6 weeks [<xref rid="ofaf315-B5" ref-type="bibr">5&#8211;7</xref>]. Outpatient parenteral antimicrobial therapy (OPAT) is often employed in such cases, typically requiring the placement of a long-term central venous catheter (CVC) [<xref rid="ofaf315-B8" ref-type="bibr">8</xref>]. Oral antimicrobial therapy or long-acting injectable agents may provide safe and effective options as well, but uptake of these strategies has been slow [<xref rid="ofaf315-B9" ref-type="bibr">9&#8211;13</xref>].</p><p>Administering OPAT to patients with a history of SUD presents a complex challenge. Surveys indicate that healthcare providers often express hesitation toward offering OPAT to these patients due to concerns about misuse of the catheter, CVC events, drug overdose risks, and even legal repercussions [<xref rid="ofaf315-B14" ref-type="bibr">14</xref>, <xref rid="ofaf315-B15" ref-type="bibr">15</xref>]. However, this hesitancy contradicts patient experiences as studies reveal that many patients with SUD express feelings of unfair judgment, impersonal treatment, and stigmatization, despite their confidence in safely using a CVC [<xref rid="ofaf315-B16" ref-type="bibr">16</xref>].</p><p>Despite extensive reviews, there remains a significant gap in our understanding of optimal OPAT management for individuals with SUD [<xref rid="ofaf315-B8" ref-type="bibr">8</xref>, <xref rid="ofaf315-B17" ref-type="bibr">17</xref>]. While several small-scale studies, including 1 prospective observational study, suggest that OPAT outcomes may not differ significantly between patients with and without a history of SUD [<xref rid="ofaf315-B18" ref-type="bibr">18&#8211;21</xref>], there are a lack of data on readmission rates and complications specifically in patients with SUD receiving multiweek OPAT after hospital discharge. This study aims to address this gap by comparing readmission rates, drug overdose rates, and CVC events between patients with and without a history of SUD who received multiweek OPAT following hospital discharge.</p><sec sec-type="methods" id="ofaf315-s1"><title>METHODS</title><sec id="ofaf315-s1.1"><title>Study Design and Population</title><p>This retrospective cohort study compared baseline characteristics, OPAT duration, rates of readmission, drug overdose, and treatment complications including CVC events between individuals with and without a history of SUD. We analyzed data from the Merative MarketScan Databases from 2015 to 2020.</p><p>We included adults (&#8805;18 years) who received at least 7 consecutive days of parenteral antibacterial therapy following hospital discharge in the outpatient setting, identified by National Drug Codes (NDCs) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>). The index date was defined as the service date of the first prescribed parenteral antimicrobial to be administered in the outpatient setting. OPAT completion was determined by adding the prescribed days&#8217; supply to the service date of the last included prescription (potentially including multiple prescriptions from the NDCs in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>) to create a complete OPAT course. Prescriptions were considered part of the same course if dispensed within two days of the prior prescription ending.</p><p>Patients were excluded if antimicrobial therapy commenced more than one day after discharge, had end-stage renal disease (ESRD), had International Classification of Diseases (ICD)-10-CM codes for <italic toggle="yes">Clostridioides difficile</italic> enterocolitis, or lacked complete insurance data. ESRD exclusion stemmed from the potential for these patients to receive antibacterial therapies during hemodialysis sessions, negating the need for dedicated vascular access devices for OPAT. Additionally, ESRD could complicate identifying isolated OPAT courses. Patients with <italic toggle="yes">C difficile</italic> enterocolitis were excluded as compounded oral vancomycin solution using injectable vancomycin powder could share NDCs with systemic vancomycin, potentially confounding our analysis.</p><p>Patients were categorized into 2 cohorts based on documented SUD history. SUD history was based on any previous diagnosis based on 1 or more ICD-10-CM codes for opioid, sedative, hypnotic, anxiolytic, cocaine, or other stimulant-related disorders (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 2</xref>).</p></sec><sec id="ofaf315-s1.2"><title>Data Collection</title><p>Baseline characteristics collected included age, sex, type of insurance plan, infection during index hospitalization, comorbidities, and SUD history (<xref rid="sup1" ref-type="supplementary-material">Supplementary Tables 2&#8211;4</xref>). The Elixhauser Comorbidity Index was calculated for 30-day readmissions based on ICD-10-CM diagnosis codes for comorbidities present before hospital discharge [<xref rid="ofaf315-B22" ref-type="bibr">22</xref>]. OPAT identification combined NDCs for IV antibacterial therapy (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>), evidence of CVC placement, and discharge status. The duration of OPAT spanned from the index date to the completion date. For those with SUD history, we queried the database for receipt of medications for opioid use disorder (MOUD) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 5</xref>) during the 30 days prior to the index hospitalization or during OPAT [<xref rid="ofaf315-B23" ref-type="bibr">23</xref>].</p></sec><sec id="ofaf315-s1.3"><title>Outcomes</title><p>The primary outcome was the rate of all-cause readmissions within 90 days of OPAT completion compared between patients with and without a history of SUD. Secondary outcomes included overdose and CVC events occurring during OPAT, and infection-related readmissions diagnosed within 90 days of OPAT completion identified using ICD-10-CM codes (<xref rid="sup1" ref-type="supplementary-material">Supplementary Tables 3, 6</xref>, and <xref rid="sup1" ref-type="supplementary-material">7</xref>). These outcomes were evaluated regardless of their relation to the index hospitalization. Overdose events were defined as documented overdoses involving opioids, other narcotics, or cocaine occurring between the index date and the end of OPAT. CVC events were defined as infections or complications involving the CVC during the same period. Infection-related readmissions were defined as hospitalizations coded for any of the specified infections. Those considered correlated with the index hospitalization were identified by matching ICD-10-CM codes between the initial and subsequent admission.</p></sec><sec id="ofaf315-s1.4"><title>Data Analysis</title><p>Baseline characteristics were summarized using descriptive statistics. Differences between individuals with and without documented SUD history were assessed using chi-squared or Fisher&#8217;s exact tests for categorical variables, including discharge location, antibacterial agents used, all-cause readmissions within 90 days of OPAT completion, overdose, CVC events during OPAT, and infection-related readmissions within 90 days. Continuous variables, such as OPAT duration, were compared using <italic toggle="yes">t</italic>-tests.</p><p>Multivariable logistic regression was performed to evaluate the association between SUD history and 90-day readmission, overdose, and CVC events. Covariates were selected a priori based on clinical relevance and prior literature and categorized into demographic variables (eg, age, sex), clinical characteristics (eg, mental health diagnoses, HIV, retained foreign body fragments, index infection type), and system-level factors (eg, discharge location, insurance type) [<xref rid="ofaf315-B24" ref-type="bibr">24</xref>, <xref rid="ofaf315-B25" ref-type="bibr">25</xref>]. Bivariate analyses were conducted to explore unadjusted associations; however, covariate selection was not based solely on statistical significance. Several covariates were retained across all models due to their clinical relevance (eg, retained foreign body fragments), policy importance (eg, insurance type), or relevance to the study audience. This approach ensured transparency, appropriate adjustment for confounding, and interpretability of both significant and null results. For consistency and comparability, all models included the same covariates. Adjusted odds ratios (OR) with 95% confidence intervals (CI) were calculated. All statistical analyses were performed using SAS software, version 9.4 (SAS Institute Inc., Cary, NC, USA).</p><p>This study is reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist (<xref rid="sup1" ref-type="supplementary-material">supplement</xref>) [<xref rid="ofaf315-B26" ref-type="bibr">26</xref>].</p></sec><sec id="ofaf315-s1.5"><title>Ethical Considerations</title><p>The Merative MarketScan Databases are fully deidentified, complying with the Health Insurance Portability and Affordability Privacy Rule. Consequently, the University of Georgia institutional review board deemed institutional review board review and approval unnecessary (PROJECT00007316).</p></sec></sec><sec sec-type="results" id="ofaf315-s2"><title>RESULTS</title><p>A total of 5903 patients were discharged with OPAT. Of these, 18% (n = 1058) had a documented history of SUD. Among those with SUD, opioid use disorder (OUD) was most prevalent (74%), followed by cocaine (26.9%), other stimulants (19.5%), and sedative, hypnotic, or anxiolytic use (8.9%). Compared to patients without SUD, those with SUD were younger, more likely to have comprehensive insurance, and less likely to be enrolled in preferred provider organization plans (<xref rid="ofaf315-T1" ref-type="table">Table 1</xref>). They also had higher rates of bacteremia, central nervous system infections, infective endocarditis, and respiratory infections. Comorbid conditions such as HIV, hepatitis C, mental health disorders, retained foreign body fragments, and housing instability were more prevalent in the SUD group, whereas diabetes mellitus, organ transplant history, and use of immunosuppressive therapy were more common among those without SUD. Other clinical characteristics and readmission risk scores were largely similar between groups.</p><table-wrap position="float" id="ofaf315-T1" orientation="portrait"><label>Table 1.</label><caption><p>Baseline Characteristics of Patients With and Without a History of SUD</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">SUD<break/>n = 1058</th><th align="center" rowspan="1" colspan="1">No SUD<break/>n = 4845</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (y), median (IQR)</td><td rowspan="1" colspan="1">48 (37&#8211;57)</td><td rowspan="1" colspan="1">55 (44&#8211;62)</td></tr><tr><td rowspan="1" colspan="1">Male sex, n (%)</td><td rowspan="1" colspan="1">551 (52.1)</td><td rowspan="1" colspan="1">2717 (56.1)</td></tr><tr><td colspan="3" rowspan="1">Type of insurance plan, n (%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;CDHP/HDHP</td><td rowspan="1" colspan="1">1 (0.1)</td><td rowspan="1" colspan="1">49 (1.0)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Comprehensive</td><td rowspan="1" colspan="1">812 (76.8)</td><td rowspan="1" colspan="1">3195 (65.9)</td></tr><tr><td rowspan="1" colspan="1">&#8195;EPO/HMO</td><td rowspan="1" colspan="1">223 (21.1)</td><td rowspan="1" colspan="1">777 (16.0)</td></tr><tr><td rowspan="1" colspan="1">&#8195;POS/POS with capitation</td><td rowspan="1" colspan="1">2 (0.2)</td><td rowspan="1" colspan="1">46 (1.0)</td></tr><tr><td rowspan="1" colspan="1">&#8195;PPO</td><td rowspan="1" colspan="1">20 (1.9)</td><td rowspan="1" colspan="1">778 (16.1)</td></tr><tr><td colspan="3" rowspan="1">Infections during index hospitalization, n (%)<sup><xref rid="tblfn2" ref-type="table-fn">a</xref></sup></td></tr><tr><td rowspan="1" colspan="1">&#8195;Bacteremia</td><td rowspan="1" colspan="1">192 (18.0)</td><td rowspan="1" colspan="1">722 (14.9)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Central nervous system infection</td><td rowspan="1" colspan="1">86 (8.1)</td><td rowspan="1" colspan="1">226 (4.7)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Infective endocarditis</td><td rowspan="1" colspan="1">156 (14.7)</td><td rowspan="1" colspan="1">342 (7.1)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Intra-abdominal infection</td><td rowspan="1" colspan="1">6 (0.6)</td><td rowspan="1" colspan="1">64 (1.3)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Joint infection</td><td rowspan="1" colspan="1">93 (8.7)</td><td rowspan="1" colspan="1">363 (7.5)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Osteomyelitis</td><td rowspan="1" colspan="1">365 (34.3)</td><td rowspan="1" colspan="1">1592 (32.9)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Prosthetic device, hardware, or graft infection</td><td rowspan="1" colspan="1">196 (18.5)</td><td rowspan="1" colspan="1">882 (18.2)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Respiratory infection</td><td rowspan="1" colspan="1">158 (14.8)</td><td rowspan="1" colspan="1">464 (9.6)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Sepsis and other non-specific infections</td><td rowspan="1" colspan="1">405 (38.0)</td><td rowspan="1" colspan="1">1780 (36.8)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Skin and soft-tissue infection</td><td rowspan="1" colspan="1">382 (35.9)</td><td rowspan="1" colspan="1">1961 (40.5)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Urinary tract infection</td><td rowspan="1" colspan="1">80 (7.5)</td><td rowspan="1" colspan="1">456 (9.4)</td></tr><tr><td colspan="3" rowspan="1">Comorbidities and underlying conditions, n (%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Cardiac arrythmias</td><td rowspan="1" colspan="1">350 (33.1)</td><td rowspan="1" colspan="1">1491 (30.8)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Diabetes mellitus</td><td rowspan="1" colspan="1">454 (42.9)</td><td rowspan="1" colspan="1">2528 (52.2)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Heart failure</td><td rowspan="1" colspan="1">260 (24.6)</td><td rowspan="1" colspan="1">1173 (24.2)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Hepatitis C virus</td><td rowspan="1" colspan="1">289 (27.3)</td><td rowspan="1" colspan="1">273 (5.6)</td></tr><tr><td rowspan="1" colspan="1">&#8195;HIV</td><td rowspan="1" colspan="1">26 (2.5)</td><td rowspan="1" colspan="1">65 (1.3)</td></tr><tr><td rowspan="1" colspan="1">&#8195;History of solid organ transplantation</td><td rowspan="1" colspan="1">3 (0.3)</td><td rowspan="1" colspan="1">81 (1.7)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Mental health disorder</td><td rowspan="1" colspan="1">693 (65.5)</td><td rowspan="1" colspan="1">2003 (41.4)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Retained foreign body fragments</td><td rowspan="1" colspan="1">20 (1.9)</td><td rowspan="1" colspan="1">38 (0.8)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Presence of orthopedic joint implant</td><td rowspan="1" colspan="1">150 (14.2)</td><td rowspan="1" colspan="1">630 (13.0)</td></tr><tr><td rowspan="1" colspan="1">&#8195;History of antineoplastic chemotherapy, monoclonal antibodies, systemic glucocorticoids, or immunosuppressive therapy</td><td rowspan="1" colspan="1">11 (1.0)</td><td rowspan="1" colspan="1">91 (1.9)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Documented resistance to antibiotics</td><td rowspan="1" colspan="1">19 (1.8)</td><td rowspan="1" colspan="1">77 (1.6)</td></tr><tr><td rowspan="1" colspan="1">Elixhauser Comorbidity Index, 30-d all-cause readmission, median (IQR)</td><td rowspan="1" colspan="1">4 (2&#8211;7)</td><td rowspan="1" colspan="1">4 (0&#8211;7)</td></tr><tr><td rowspan="1" colspan="1">Housing instability or homelessness, n (%)</td><td rowspan="1" colspan="1">28 (2.7)</td><td rowspan="1" colspan="1">29 (0.6)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>Abbreviations: CDHP/HDHP, Consumer-directed health plan/high-deductible health plan; EPO/HMO, exclusive provider organization/health maintenance organization; IQR, interquartile range; POS, point of service; PPO, preferred provider organization; SUD, substance use disorders.</p></fn><fn id="tblfn2"><p>
<sup>a</sup>Individuals could have more than 1 index infection.</p></fn></table-wrap-foot></table-wrap><p>Discharge locations differed significantly between groups (<italic toggle="yes">P</italic> &lt; .001) (<xref rid="ofaf315-T2" ref-type="table">Table 2</xref>). Although most patients were discharged home (65.8% in the SUD group and 79.6% in the group without SUD), those with SUD were more likely to be discharged to skilled nursing facilities or other institutional settings (31.8% vs 17.1%).</p><table-wrap position="float" id="ofaf315-T2" orientation="portrait"><label>Table 2.</label><caption><p>Discharge Location and Antibacterial Therapies Administered During OPAT in Patients With and Without a History of SUD</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">SUD<break/>n = 1058</th><th align="center" rowspan="1" colspan="1">No SUD<break/>n = 4845</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Discharge location, n (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Home</td><td rowspan="1" colspan="1">694 (65.8)</td><td rowspan="1" colspan="1">3858 (79.6)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Skilled nursing facilities or other institutional settings</td><td rowspan="1" colspan="1">336 (31.8)</td><td rowspan="1" colspan="1">828 (17.1)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Other<sup><xref rid="tblfn4" ref-type="table-fn">a</xref></sup></td><td rowspan="1" colspan="1">28 (2.7)</td><td rowspan="1" colspan="1">159 (3.3)</td><td rowspan="1" colspan="1"/></tr><tr><td colspan="4" rowspan="1">Antibacterial agents administered during OPAT, n (%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Cefazolin</td><td rowspan="1" colspan="1">199 (18.8)</td><td rowspan="1" colspan="1">840 (17.3)</td><td rowspan="1" colspan="1">.274</td></tr><tr><td rowspan="1" colspan="1">&#8195;Daptomycin</td><td rowspan="1" colspan="1">116 (11.0)</td><td rowspan="1" colspan="1">518 (10.7)</td><td rowspan="1" colspan="1">.838</td></tr><tr><td rowspan="1" colspan="1">&#8195;Nafcillin</td><td rowspan="1" colspan="1">53 (5.0)</td><td rowspan="1" colspan="1">230 (4.8)</td><td rowspan="1" colspan="1">.778</td></tr><tr><td rowspan="1" colspan="1">&#8195;Oxacillin</td><td rowspan="1" colspan="1">24 (2.4)</td><td rowspan="1" colspan="1">104 (2.2)</td><td rowspan="1" colspan="1">.749</td></tr><tr><td rowspan="1" colspan="1">&#8195;Vancomycin</td><td rowspan="1" colspan="1">700 (66.2)</td><td rowspan="1" colspan="1">3286 (67.8)</td><td rowspan="1" colspan="1">.313</td></tr><tr><td rowspan="1" colspan="1">Duration of OPAT (d), median (IQR)</td><td rowspan="1" colspan="1">20 (11&#8211;31)</td><td rowspan="1" colspan="1">19 (11&#8211;33)</td><td rowspan="1" colspan="1">.492</td></tr></tbody></table><table-wrap-foot><fn id="tblfn3"><p>Abbreviations: IQR, interquartile range; OPAT, outpatient parenteral antimicrobial therapy; SUD, substance use disorder.</p></fn><fn id="tblfn4"><p>
<sup>a</sup>Other includes transfer to another acute care facility for inpatient admission, left against medical advice, &#8220;other alive status,&#8221; &#8220;still patient,&#8221; hospice.</p></fn></table-wrap-foot></table-wrap><p>The use of antibacterial agents during OPAT was comparable between the groups. Vancomycin was most common in both cohorts (66.2% and 67.8% in SUD and non-SUD groups, respectively). Rates of other antibacterial agents, including daptomycin, nafcillin, oxacillin, and cefazolin, were lower but similar between the groups. The median duration of OPAT was similar between patients with and without SUD (20 days vs 19 days, <italic toggle="yes">P</italic> = .492).</p><p>Patients with SUD experienced significantly higher rates of 90-day all-cause readmission following OPAT completion compared to those without SUD (40.1% vs 32.5%, <italic toggle="yes">P</italic> &lt; .001) (<xref rid="ofaf315-T3" ref-type="table">Table 3</xref>). They also had higher rates of overdose events (1.2% vs 0.1%, <italic toggle="yes">P</italic> &lt; .001), driven primarily by opioid or other narcotic overdoses (1.1% vs 0.1%, <italic toggle="yes">P</italic> &lt; .001), whereas cocaine-related overdoses were uncommon and occurred at similar rates between groups (0.1% vs 0%, <italic toggle="yes">P</italic> = .179). In contrast, CVC event rates were comparable between patients with and without SUD (6.5% vs 5.3%, <italic toggle="yes">P</italic> = .137) with no significant differences observed in the incidence of CVC-related infections (3.5% vs 3.1%, <italic toggle="yes">P</italic> = .613) or other complications (3.0% vs 2.3%, <italic toggle="yes">P</italic> = .166).</p><table-wrap position="float" id="ofaf315-T3" orientation="portrait"><label>Table 3.</label><caption><p>Outcomes Among Patients With and Without a History of SUD</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">SUD<break/>n = 1058</th><th align="center" rowspan="1" colspan="1">No SUD<break/>n = 4845</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">90-d all-cause readmission, n (%)</td><td rowspan="1" colspan="1">424 (40.1)</td><td rowspan="1" colspan="1">1574 (32.5)</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td colspan="4" rowspan="1">Overdose between index date and date of completion of the associated OPAT course, n (%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Composite</td><td rowspan="1" colspan="1">13 (1.2)</td><td rowspan="1" colspan="1">6 (0.1)</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Opioid or other narcotic</td><td rowspan="1" colspan="1">12 (1.1)</td><td rowspan="1" colspan="1">6 (0.1)</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Cocaine</td><td rowspan="1" colspan="1">1 (0.1)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">.179</td></tr><tr><td colspan="4" rowspan="1">Central venous catheter events between index date and date of completion of the associated OPAT course, n (%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Composite</td><td rowspan="1" colspan="1">69 (6.5)</td><td rowspan="1" colspan="1">256 (5.3)</td><td rowspan="1" colspan="1">.137</td></tr><tr><td rowspan="1" colspan="1">&#8195;Infection</td><td rowspan="1" colspan="1">37 (3.5)</td><td rowspan="1" colspan="1">152 (3.1)</td><td rowspan="1" colspan="1">.613</td></tr><tr><td rowspan="1" colspan="1">&#8195;Complication</td><td rowspan="1" colspan="1">32 (3.0)</td><td rowspan="1" colspan="1">109 (2.3)</td><td rowspan="1" colspan="1">.166</td></tr><tr><td colspan="4" rowspan="1">Infection-related readmissions, n (%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Composite</td><td rowspan="1" colspan="1">392 (92.5)</td><td rowspan="1" colspan="1">1389 (88.2)</td><td rowspan="1" colspan="1">.024</td></tr><tr><td rowspan="1" colspan="1">&#8195;Bacteremia</td><td rowspan="1" colspan="1">44 (10.4)</td><td rowspan="1" colspan="1">105 (6.7)</td><td rowspan="1" colspan="1">.013</td></tr><tr><td rowspan="1" colspan="1">&#8195;Central nervous system infection</td><td rowspan="1" colspan="1">23 (5.4)</td><td rowspan="1" colspan="1">51 (3.2)</td><td rowspan="1" colspan="1">.050</td></tr><tr><td rowspan="1" colspan="1">&#8195;Infective endocarditis</td><td rowspan="1" colspan="1">38 (9.0)</td><td rowspan="1" colspan="1">47 (3.0)</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Intra-abdominal infection</td><td rowspan="1" colspan="1">3 (0.7)</td><td rowspan="1" colspan="1">26 (1.7)</td><td rowspan="1" colspan="1">.223</td></tr><tr><td rowspan="1" colspan="1">&#8195;Joint infection</td><td rowspan="1" colspan="1">35 (8.2)</td><td rowspan="1" colspan="1">88 (5.6)</td><td rowspan="1" colspan="1">.058</td></tr><tr><td rowspan="1" colspan="1">&#8195;Osteomyelitis</td><td rowspan="1" colspan="1">113 (26.7)</td><td rowspan="1" colspan="1">399 (25.4)</td><td rowspan="1" colspan="1">.630</td></tr><tr><td rowspan="1" colspan="1">&#8195;Prosthetic device, hardware, or graft infection</td><td rowspan="1" colspan="1">96 (22.6)</td><td rowspan="1" colspan="1">320 (20.3)</td><td rowspan="1" colspan="1">.342</td></tr><tr><td rowspan="1" colspan="1">&#8195;Respiratory infection</td><td rowspan="1" colspan="1">73 (17.2)</td><td rowspan="1" colspan="1">174 (11.1)</td><td rowspan="1" colspan="1">.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Sepsis and other nonspecific infections</td><td rowspan="1" colspan="1">186 (43.8)</td><td rowspan="1" colspan="1">608 (38.6)</td><td rowspan="1" colspan="1">.062</td></tr><tr><td rowspan="1" colspan="1">&#8195;Skin and soft-tissue infection</td><td rowspan="1" colspan="1">140 (32.9)</td><td rowspan="1" colspan="1">576 (36.6)</td><td rowspan="1" colspan="1">.181</td></tr><tr><td rowspan="1" colspan="1">&#8195;Urinary tract infection</td><td rowspan="1" colspan="1">44 (10.4)</td><td rowspan="1" colspan="1">173 (11.0)</td><td rowspan="1" colspan="1">.774</td></tr><tr><td colspan="4" rowspan="1">Infection-related readmissions correlated with index hospitalization, n (%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Bacteremia</td><td rowspan="1" colspan="1">17 (8.9)</td><td rowspan="1" colspan="1">36 (5.0)</td><td rowspan="1" colspan="1">.062</td></tr><tr><td rowspan="1" colspan="1">&#8195;Central nervous system infection</td><td rowspan="1" colspan="1">11 (12.8)</td><td rowspan="1" colspan="1">20 (8.8)</td><td rowspan="1" colspan="1">.408</td></tr><tr><td rowspan="1" colspan="1">&#8195;Infective endocarditis</td><td rowspan="1" colspan="1">26 (16.7)</td><td rowspan="1" colspan="1">29 (8.5)</td><td rowspan="1" colspan="1">.011</td></tr><tr><td rowspan="1" colspan="1">&#8195;Intra-abdominal infection</td><td rowspan="1" colspan="1">1 (16.7)</td><td rowspan="1" colspan="1">8 (12.5)</td><td rowspan="1" colspan="1">.577</td></tr><tr><td rowspan="1" colspan="1">&#8195;Joint infection</td><td rowspan="1" colspan="1">13 (14.0)</td><td rowspan="1" colspan="1">29 (8.0)</td><td rowspan="1" colspan="1">.114</td></tr><tr><td rowspan="1" colspan="1">&#8195;Osteomyelitis</td><td rowspan="1" colspan="1">83 (22.7)</td><td rowspan="1" colspan="1">295 (18.5)</td><td rowspan="1" colspan="1">.078</td></tr><tr><td rowspan="1" colspan="1">&#8195;Prosthetic device, hardware, or graft infection</td><td rowspan="1" colspan="1">43 (21.9)</td><td rowspan="1" colspan="1">143 (16.2)</td><td rowspan="1" colspan="1">.070</td></tr><tr><td rowspan="1" colspan="1">&#8195;Respiratory infection</td><td rowspan="1" colspan="1">32 (20.3)</td><td rowspan="1" colspan="1">52 (11.2)</td><td rowspan="1" colspan="1">.006</td></tr><tr><td rowspan="1" colspan="1">&#8195;Sepsis and other nonspecific infections</td><td rowspan="1" colspan="1">62 (15.3)</td><td rowspan="1" colspan="1">218 (12.2)</td><td rowspan="1" colspan="1">.114</td></tr><tr><td rowspan="1" colspan="1">&#8195;Skin and soft-tissue infection</td><td rowspan="1" colspan="1">54 (14.1)</td><td rowspan="1" colspan="1">225 (11.5)</td><td rowspan="1" colspan="1">.167</td></tr><tr><td rowspan="1" colspan="1">&#8195;Urinary tract infection</td><td rowspan="1" colspan="1">16 (20.0)</td><td rowspan="1" colspan="1">77 (16.9)</td><td rowspan="1" colspan="1">.604</td></tr></tbody></table><table-wrap-foot><fn id="tblfn5"><p>Abbreviations: OPAT, outpatient parenteral antimicrobial therapy; SUD, substance use disorder.</p></fn></table-wrap-foot></table-wrap><p>Among patients readmitted within 90 days of OPAT completion, infection-related readmissions were more common in those with SUD (92.5% vs 88.2%, <italic toggle="yes">P</italic> = .024). They were readmitted at higher rates for bacteremia (10.4% vs 6.7%, <italic toggle="yes">P</italic> = .013), infective endocarditis (9.0% vs 3.0%, <italic toggle="yes">P</italic> &lt; .001), and respiratory infections (17.2% vs 11.1%, <italic toggle="yes">P</italic> = .001), whereas rates of other infections were similar. Readmission for the same infection as the index hospitalization was more frequent in the SUD group for infective endocarditis (16.7% vs 8.5%, <italic toggle="yes">P</italic> = .011) and respiratory infection (20.3% vs 11.2%, <italic toggle="yes">P</italic> = .006), whereas rates for other infections were comparable.</p><p>Outcomes among patients with SUD were similar regardless of discharge location, with no significant differences in 90-day all-cause readmission (40.3% vs 38.4%, <italic toggle="yes">P</italic> = .643) and composite overdose (1.0% vs 1.8%, <italic toggle="yes">P</italic> = .371) between those discharged home or to institutional settings (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 8</xref>). However, patients discharged home had higher rates of CVC-related infections (4.4% vs 1.8%, <italic toggle="yes">P</italic> = .048) and sepsis-related readmissions (19.1% vs 10.3%, <italic toggle="yes">P</italic> = .022), whereas those discharged to institutional settings had increased rates of infective endocarditis (17.8% vs 5.0%, <italic toggle="yes">P</italic> &lt; .0001) and respiratory infection readmissions (26.4% vs 13.2%, <italic toggle="yes">P</italic> = .001). Prosthetic device infections were more frequent among patients discharged home (28.2% vs 10.9%, <italic toggle="yes">P</italic> = .0002).</p><p>MOUD was prescribed to 6% of patients with SUD, representing 62 individuals in this cohort. Notably, MOUD receipt was not associated with significant differences in clinical outcomes (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 9</xref>). Rates of all-cause readmission within 90 days were comparable between those who received MOUD and those who did not (45.2% vs 39.9%, <italic toggle="yes">P</italic> = .461). Similarly, no significant differences were observed in composite overdose events (0% vs 1.3%, <italic toggle="yes">P</italic> = 1), CVC-related infections (6.5% vs 3.3%, <italic toggle="yes">P</italic> = .268), or composite CVC events (6.5% vs 6.5%, <italic toggle="yes">P</italic> = 1). Infection-related readmissions were also similar (92.9% vs 92.2%, <italic toggle="yes">P</italic> = 1).</p><p>In multivariable logistic regression models, SUD was not associated with increased odds of readmission (OR 1.16; 95% CI, .99&#8211;1.34; <italic toggle="yes">P</italic> = .067) (<xref rid="ofaf315-T4" ref-type="table">Table 4</xref>). Insurance type was a strong predictor of readmission risk. Specifically, patients with point-of-service or point-of-service&#8211;capitation plans had significantly higher odds of readmission compared to other insurance types (OR 3.24; 95% CI, 1.18&#8211;9.68; <italic toggle="yes">P</italic> = .027). Mental health disorders were also associated with increased readmission risk (OR 1.07; 95% CI, 1.02&#8211;1.12; <italic toggle="yes">P</italic> = .006). Conversely, discharge to home (OR 0.85; 95% CI, .73&#8211;0.98; <italic toggle="yes">P</italic> = .027) and greater cumulative antibacterial supply (OR 0.99; 95% CI, .99&#8211;.99; <italic toggle="yes">P</italic> &lt; .001) were associated with reduced odds of readmission. Age, sex, HIV, retained foreign body fragments, housing instability, and receipt of MOUD were not significantly associated with readmission.</p><table-wrap position="float" id="ofaf315-T4" orientation="portrait"><label>Table 4.</label><caption><p>Multivariable Logistic Regression Results for 90-Day Readmission</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Odds Ratio</th><th align="center" rowspan="1" colspan="1">95% Confidence Interval</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">1.00</td><td rowspan="1" colspan="1">.99&#8211;1.00</td><td rowspan="1" colspan="1">.087</td></tr><tr><td rowspan="1" colspan="1">Comprehensive insurance</td><td rowspan="1" colspan="1">1.67</td><td rowspan="1" colspan="1">.72&#8211;4.39</td><td rowspan="1" colspan="1">.257</td></tr><tr><td rowspan="1" colspan="1">Cumulative supply</td><td rowspan="1" colspan="1">0.99</td><td rowspan="1" colspan="1">.99&#8211;.99</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">Discharge home</td><td rowspan="1" colspan="1">0.85</td><td rowspan="1" colspan="1">.73&#8211;.98</td><td rowspan="1" colspan="1">.027</td></tr><tr><td rowspan="1" colspan="1">EPO/HMO insurance</td><td rowspan="1" colspan="1">1.47</td><td rowspan="1" colspan="1">.63&#8211;3.85</td><td rowspan="1" colspan="1">.397</td></tr><tr><td rowspan="1" colspan="1">HIV</td><td rowspan="1" colspan="1">1.07</td><td rowspan="1" colspan="1">.68&#8211;1.65</td><td rowspan="1" colspan="1">.775</td></tr><tr><td rowspan="1" colspan="1">Housing instability</td><td rowspan="1" colspan="1">1.12</td><td rowspan="1" colspan="1">.64&#8211;1.92</td><td rowspan="1" colspan="1">.692</td></tr><tr><td colspan="4" rowspan="1">Infections during index hospitalization<sup><xref rid="tblfn7" ref-type="table-fn">a</xref></sup></td></tr><tr><td rowspan="1" colspan="1">&#8195;Bacteremia</td><td rowspan="1" colspan="1">0.88</td><td rowspan="1" colspan="1">.75&#8211;1.03</td><td rowspan="1" colspan="1">.115</td></tr><tr><td rowspan="1" colspan="1">&#8195;Central nervous system infection</td><td rowspan="1" colspan="1">1.16</td><td rowspan="1" colspan="1">1.01&#8211;1.32</td><td rowspan="1" colspan="1">.030</td></tr><tr><td rowspan="1" colspan="1">&#8195;Infective endocarditis</td><td rowspan="1" colspan="1">0.87</td><td rowspan="1" colspan="1">.70&#8211;1.08</td><td rowspan="1" colspan="1">.214</td></tr><tr><td rowspan="1" colspan="1">&#8195;Intra-abdominal infection</td><td rowspan="1" colspan="1">0.61</td><td rowspan="1" colspan="1">.46&#8211;.80</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Joint infection</td><td rowspan="1" colspan="1">1.42</td><td rowspan="1" colspan="1">.85&#8211;2.34</td><td rowspan="1" colspan="1">.171</td></tr><tr><td rowspan="1" colspan="1">&#8195;Osteomyelitis</td><td rowspan="1" colspan="1">0.70</td><td rowspan="1" colspan="1">.55&#8211;.87</td><td rowspan="1" colspan="1">.002</td></tr><tr><td rowspan="1" colspan="1">&#8195;Prosthetic device, hardware, or graft infection</td><td rowspan="1" colspan="1">1.46</td><td rowspan="1" colspan="1">1.25&#8211;1.69</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Respiratory infection</td><td rowspan="1" colspan="1">1.20</td><td rowspan="1" colspan="1">1.00&#8211;1.45</td><td rowspan="1" colspan="1">.053</td></tr><tr><td rowspan="1" colspan="1">&#8195;Sepsis and other nonspecific infections</td><td rowspan="1" colspan="1">1.11</td><td rowspan="1" colspan="1">.98&#8211;1.25</td><td rowspan="1" colspan="1">.096</td></tr><tr><td rowspan="1" colspan="1">&#8195;Skin and soft-tissue infection</td><td rowspan="1" colspan="1">0.79</td><td rowspan="1" colspan="1">.70&#8211;.90</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Urinary tract infection</td><td rowspan="1" colspan="1">1.26</td><td rowspan="1" colspan="1">1.03&#8211;1.53</td><td rowspan="1" colspan="1">.024</td></tr><tr><td rowspan="1" colspan="1">Medicare</td><td rowspan="1" colspan="1">0.74</td><td rowspan="1" colspan="1">.55&#8211;1.01</td><td rowspan="1" colspan="1">.058</td></tr><tr><td rowspan="1" colspan="1">Medicaid</td><td rowspan="1" colspan="1">1.36</td><td rowspan="1" colspan="1">.97&#8211;1.91</td><td rowspan="1" colspan="1">.079</td></tr><tr><td rowspan="1" colspan="1">Mental health disorder</td><td rowspan="1" colspan="1">1.07</td><td rowspan="1" colspan="1">1.02&#8211;1.12</td><td rowspan="1" colspan="1">.006</td></tr><tr><td rowspan="1" colspan="1">Medication for opioid use disorder</td><td rowspan="1" colspan="1">1.13</td><td rowspan="1" colspan="1">.74&#8211;1.72</td><td rowspan="1" colspan="1">.564</td></tr><tr><td rowspan="1" colspan="1">POS/POS with capitation</td><td rowspan="1" colspan="1">3.24</td><td rowspan="1" colspan="1">1.18&#8211;9.68</td><td rowspan="1" colspan="1">.027</td></tr><tr><td rowspan="1" colspan="1">PPO</td><td rowspan="1" colspan="1">1.61</td><td rowspan="1" colspan="1">.72&#8211;4.10</td><td rowspan="1" colspan="1">.273</td></tr><tr><td rowspan="1" colspan="1">Retained foreign body fragments</td><td rowspan="1" colspan="1">1.14</td><td rowspan="1" colspan="1">.66&#8211;1.96</td><td rowspan="1" colspan="1">.635</td></tr><tr><td rowspan="1" colspan="1">Male sex</td><td rowspan="1" colspan="1">0.96</td><td rowspan="1" colspan="1">.85&#8211;1.08</td><td rowspan="1" colspan="1">.481</td></tr><tr><td rowspan="1" colspan="1">Substance use disorder</td><td rowspan="1" colspan="1">1.16</td><td rowspan="1" colspan="1">.99&#8211;1.34</td><td rowspan="1" colspan="1">.067</td></tr></tbody></table><table-wrap-foot><fn id="tblfn6"><p>Abbreviations: EPO/HMO, exclusive provider organization/health maintenance organization; POS, point of service; PPO, preferred provider organization.</p></fn><fn id="tblfn7"><p>
<sup>a</sup>Individuals could have more than one index infection.</p></fn></table-wrap-foot></table-wrap><p>Infection type at index admission also influenced readmission risk. Central nervous system infections (OR 1.16; 95% CI, 1.01&#8211;1.32; <italic toggle="yes">P</italic> = .030), prosthetic device, hardware, or graft infections (OR 1.46; 95% CI, 1.25&#8211;1.69; <italic toggle="yes">P</italic> &lt; .001), and urinary tract infections (OR 1.26; 95% CI, 1.03&#8211;1.53; <italic toggle="yes">P</italic> = .024) were each associated with increased odds of readmission. In contrast, intra-abdominal infections (OR 0.61; 95% CI, .46&#8211;.80; <italic toggle="yes">P</italic> &lt; .001), osteomyelitis (OR 0.70; 95% CI, .55&#8211;.87; <italic toggle="yes">P</italic> = .002), and skin and soft-tissue infections (OR 0.79; 95% CI, .70&#8211;.90; <italic toggle="yes">P</italic> &lt; .001) were associated with decreased odds.</p><p>Patients with SUD had significantly higher odds of overdose (OR 6.03; 95% CI, 2.21&#8211;17.64; <italic toggle="yes">P</italic> &lt; .001) and male sex was also associated with increased overdose odds (OR 3.09; 95% CI, 1.18&#8211;9.24; <italic toggle="yes">P</italic> = .021) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 10</xref>).</p><p>In contrast, SUD was not associated with CVC events (OR 1.10; 95% CI, .80&#8211;1.48; <italic toggle="yes">P</italic> = .552) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 11</xref>). Older age was associated with slightly lower odds of CVC events (OR 0.99; 95% CI, .98&#8211;1.00; <italic toggle="yes">P</italic> = .049), whereas discharge to home was associated with increased odds (OR 1.58; 95% CI, 1.12&#8211;2.29; <italic toggle="yes">P</italic> = .012). Several infection types were associated with higher odds of CVC events, including bacteremia (OR 2.38; 95% CI, 1.81&#8211;3.12; <italic toggle="yes">P</italic> &lt; .001), prosthetic device, hardware, or graft infections (OR 4.23; 95% CI, 3.27&#8211;5.47; <italic toggle="yes">P</italic> &lt; .001), and sepsis or other nonspecific infections (OR 1.37; 95% CI, 1.07&#8211;1.75; <italic toggle="yes">P</italic> = .012). Osteomyelitis was associated with reduced odds of CVC events (OR 0.37; 95% CI, .20&#8211;.64; <italic toggle="yes">P</italic> = .001).</p></sec><sec sec-type="discussion" id="ofaf315-s3"><title>DISCUSSION</title><p>This study compared characteristics and outcomes of patients with and without SUD who received multiweek OPAT. Despite concerns that SUD might increase the risks associated with OPAT, our analysis found no significant difference in CVC event rates between the 2 groups, with similar odds of readmission and CVC events. These results align with studies reporting lower complication rates among people who use drugs (PWUD) [<xref rid="ofaf315-B18" ref-type="bibr">18</xref>]. Effective strategies to mitigate complications during OPAT in patients with SUD include patient education and regular line inspections [<xref rid="ofaf315-B17" ref-type="bibr">17</xref>, <xref rid="ofaf315-B19" ref-type="bibr">19</xref>, <xref rid="ofaf315-B27" ref-type="bibr">27</xref>]. One center implemented a model using a risk assessment tool to determine OPAT candidacy among PWUD, which reduced costs and length of stay without increasing readmissions [<xref rid="ofaf315-B28" ref-type="bibr">28</xref>]. Other strategies, such as broader use of oral or long-acting injectable antimicrobials [<xref rid="ofaf315-B9" ref-type="bibr">9</xref>, <xref rid="ofaf315-B10" ref-type="bibr">10</xref>, <xref rid="ofaf315-B29" ref-type="bibr">29</xref>], may also yield favorable outcomes, though our study did not capture data on their usage or effects.</p><p>Many centers have experience using OPAT for PWUD, despite safety concerns. An international survey reported that 84% of OPAT programs have treated PWUD, whereas only 11% excluded them from treatment [<xref rid="ofaf315-B30" ref-type="bibr">30</xref>]. Although clinician opinions on the safety of OPAT for PWUD vary, many believe the benefits outweigh the risks. In contrast, studies conducted in the United States reveal lower clinician confidence in providing OPAT to PWUD [<xref rid="ofaf315-B14" ref-type="bibr">14</xref>, <xref rid="ofaf315-B15" ref-type="bibr">15</xref>, <xref rid="ofaf315-B31" ref-type="bibr">31</xref>]. Common concerns include the risk of illicit drug use through the vascular catheter, catheter misuse, and socioeconomic challenges leading to decreased follow-up and treatment completion [<xref rid="ofaf315-B14" ref-type="bibr">14</xref>, <xref rid="ofaf315-B15" ref-type="bibr">15</xref>]. Despite these concerns, our study found that the median duration of OPAT was similar between groups and within the range of 18 to 42 days reported in previous studies [<xref rid="ofaf315-B17" ref-type="bibr">17</xref>]. Although our claims data could not directly assess treatment completion rates, literature suggests that OPAT completion rates in individuals with SUD range from 72% to 100%, and closer follow-up could potentially improve adherence [<xref rid="ofaf315-B17" ref-type="bibr">17</xref>].</p><p>Discharge locations differed significantly between the groups. Patients with SUD were more likely to discharge to skilled nursing facilities or other institutional settings, potentially reflecting concerns about housing instability, medication adherence, or social support limitations. Comorbid mental health disorders and chronic conditions in the SUD group could have also impacted their candidacy for home-based OPAT [<xref rid="ofaf315-B32" ref-type="bibr">32&#8211;35</xref>]. SUD can complicate adherence to mental health treatment, further complicating OPAT management [<xref rid="ofaf315-B36" ref-type="bibr">36</xref>].</p><p>Patients with SUD experienced higher unadjusted rates of 90-day readmission, primarily due to infection-related causes such as bacteremia, infective endocarditis, and respiratory infections. However, after adjusting for other risk factors, SUD was not independently associated with increased readmission odds. Instead, insurance type, mental health comorbidities, and discharge to home significantly predicted readmission risk, whereas discharge to home was also associated with higher odds of CVC events. Prior studies have reported similar rates of treatment failure, infection relapse, hospital readmission, and short-term mortality between patients with and without SUD [<xref rid="ofaf315-B21" ref-type="bibr">21</xref>], although such findings may reflect differences in study design, outcome definitions, or the methods used to identify SUD. One factor that may contribute to these variations is discharge disposition. In our study, 31.8% of patients with SUD were discharged to skilled nursing facilities or other institutional settings, compared to 82% in a prior study of patients with a history of injection drug use [<xref rid="ofaf315-B21" ref-type="bibr">21</xref>]. The structured environment of skilled nursing facilities may theoretically support adherence and reduce complications among patients with SUD receiving OPAT, but data on institutional stay duration or sobriety during OPAT limit conclusions about the direct impact of discharge location on clinical outcomes.</p><p>Individuals with a history of drug use often have higher baseline hospitalization rates [<xref rid="ofaf315-B37" ref-type="bibr">37</xref>]. The significantly higher overdose rate in the SUD group emphasizes the need for comprehensive care, including potential SUD treatment integration, access to sterile injection equipment, overdose prevention programs, naloxone rescue distribution, and safer injection training [<xref rid="ofaf315-B20" ref-type="bibr">20</xref>, <xref rid="ofaf315-B27" ref-type="bibr">27</xref>, <xref rid="ofaf315-B38" ref-type="bibr">38&#8211;40</xref>]. Addressing underlying SUD, particularly OUD, could improve OPAT outcomes among those with SUD. A pilot study of buprenorphine treatment for OUD in patients requiring IV antibiotics found comparable success rates between home-based OPAT and hospital-based therapy [<xref rid="ofaf315-B41" ref-type="bibr">41</xref>, <xref rid="ofaf315-B42" ref-type="bibr">42</xref>]. However, our multivariable logistic regression analysis did not find significant impacts of MOUD on readmission, overdose, or CVC events. This discrepancy may stem from incomplete or inconsistent MOUD documentation in insurance claims databases, leading to possible misclassification bias [<xref rid="ofaf315-B43" ref-type="bibr">43</xref>].</p><p>The success of OPAT for SUD depends on multiple factors, including the severity of SUD, access to SUD treatment, and the willingness of infusion companies to support these patients [<xref rid="ofaf315-B44" ref-type="bibr">44</xref>]. Although OPAT remains a valuable treatment option, alternative approaches such as oral therapy and long-acting glycopeptides should be considered, especially in light of growing evidence and guidelines [<xref rid="ofaf315-B9" ref-type="bibr">9</xref>, <xref rid="ofaf315-B10" ref-type="bibr">10</xref>, <xref rid="ofaf315-B14" ref-type="bibr">14</xref>, <xref rid="ofaf315-B45" ref-type="bibr">45</xref>, <xref rid="ofaf315-B46" ref-type="bibr">46</xref>]. However, the increased healthcare contact associated with hospital-based treatment or home health nurse visits might lead to greater adherence to IV therapy compared to oral therapy. Shared decision-making is essential for patient-centered care free from stigma.</p><p>Our findings along with previous research suggest a nuanced approach to managing infections in individuals with SUD is essential. To optimize outcomes and patient safety, a multidisciplinary team that includes experts in infectious diseases, mental health, and social work should guide decision-making and address both the infection and underlying SUD. On discharge, treatment teams should consider methods to ensure success such as risk scoring and stratification of OPAT, increased monitoring with more frequent follow-up appointments that include line inspections, and patient education regarding line maintenance and risks and benefits of OPAT.</p><p>Future research should explore the impact of interventions such as medication adherence programs, addiction treatment integration, and social support services on readmission rates and long-term outcomes for patients with SUD receiving OPAT. Identifying factors contributing to infection-related readmissions in this population is also warranted.</p></sec><sec id="ofaf315-s4"><title>LIMITATIONS</title><p>This study used the Merative MarketScan Database to examine the influence of SUD on outcomes among medically insured individuals receiving multiweek OPAT. However, the retrospective design and requirement for continuous health plan enrollment limit the generalizability of the findings. This enrollment requirement inherently restricts the patient population, as individuals with SUDs are historically less likely to have continuous insurance coverage [<xref rid="ofaf315-B47" ref-type="bibr">47</xref>]. Additionally, the institutional user agreement constrained the study period.</p><p>Large administrative claims databases have inherent limitations that require cautious interpretation of findings. Challenges include missing data, inaccurate coding, and potential misclassification of diagnoses. Individual-level factors&#8212;such as patient counseling, shared decision-making, and treatment adherence&#8212;could not be assessed, likely leading to a heterogeneous patient population with potentially suboptimal management strategies for these aspects of care. SUD history was defined based on any prior diagnosis of opioid, sedative, hypnotic, anxiolytic, cocaine, or other stimulant-related disorders. Although effective pharmacologic treatment exists for OUD, individuals with stimulant use disorder without OUD lack comparable treatment options, which may influence outcomes. Moreover, the database lacked specific diagnoses for injection drug use [<xref rid="ofaf315-B48" ref-type="bibr">48</xref>], and the accuracy of SUD billing codes is uncertain due to potential underreporting and provider discomfort discussing substance use. The inability to differentiate between specific behaviors captured by these codes hindered precise analysis.</p><p>Although this study provides valuable insights into OPAT outcomes among patients with and without SUD, it does not directly address whether OPAT is the optimal treatment strategy for patients with SUD compared to alternatives such as oral antimicrobial therapy, long-acting injectable agents, or continued hospitalization with daily IV therapy. This comparative effectiveness question is central to clinical decision-making but is difficult to assess retrospectively due to significant confounding by indication. In many real-world scenarios, particularly for patients with SUD, treatment selection is driven by a complex risk&#8211;benefit assessment. These patients may not be ideal candidates for prolonged hospitalization or placement, making all available treatment options somewhat nonstandard. Although our data provide important insights into OPAT outcomes in this population, future research directly comparing OPAT with other treatment modalities in patients with SUD is essential. Given the heterogeneity in indications and implementation of these alternative strategies, our study design does not allow for such direct comparisons. However, future studies addressing this critical question will be instrumental in guiding evidence-based care for this vulnerable population.</p></sec><sec id="ofaf315-s5"><title>CONCLUSION</title><p>Among patients receiving OPAT, 18% had a documented history of SUD, primarily opioid-related. After adjusting for relevant covariates, SUD was not independently associated with increased risk of 90-day readmission or CVC events but was a significant risk factor for overdose. These findings demonstrate the need for targeted overdose prevention rather than exclusion from OPAT, emphasizing the importance of individualized care that addresses both infectious and substance use&#8211;related needs.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>ofaf315_Supplementary_Data</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ofaf315_supplementary_data.zip" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><title>Notes</title><p>
<bold>
<italic toggle="yes">Acknowledgments.</italic>
</bold> None.</p><p>
<bold>
<italic toggle="yes">Author contributions.</italic>
</bold> D.J.R.: conceptualization (lead), data curation (supporting), formal analysis (supporting), methodology (supporting), visualization (lead), writing&#8212;original draft (lead), writing&#8212;review and editing (lead). L.Z.: data curation (lead), formal analysis (lead), methodology (lead), software (lead), writing&#8212;original draft (equal), writing&#8212;review and editing (equal). D.Z.: data curation (lead), formal analysis (lead), methodology (lead), software (lead), writing&#8212;original draft (equal), writing&#8212;review and editing (equal). X.C.: data curation (lead), formal analysis (lead), methodology (lead), supervision (lead), writing&#8212;original draft (equal), writing&#8212;review and editing (equal). M.K.: writing&#8212;original draft (equal), writing&#8212;review and editing (equal). A.F.H.M.: writing&#8212;original draft (equal), writing&#8212;review and editing (equal). D.<sc>B.c.</sc>: conceptualization (lead), data curation (supporting), formal analysis (supporting), methodology (supporting), visualization (lead), writing&#8212;original draft (lead), writing&#8212;review and editing (lead).</p><p>
<bold>
<italic toggle="yes">Patient consent statement.</italic>
</bold> This study did not include factors necessitating patient consent.</p><p>
<bold>
<italic toggle="yes">Access to data.</italic>
</bold> The data that support the findings of this study are available from the Merative Databases. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the Merative Databases through a third-party agreement option.</p><p>
<bold>
<italic toggle="yes">Financial support.</italic>
</bold> The authors received no financial support for the research, authorship, and/or publication of this article.</p></ack><sec id="ofaf315-s6"><title>Supplementary Data</title><p>
<xref rid="sup1" ref-type="supplementary-material">Supplementary materials</xref> are available at <italic toggle="yes">Open Forum Infectious Diseases</italic> online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.</p></sec><ref-list id="ref1"><title>References</title><ref id="ofaf315-B1"><label>1</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>HHS</collab></person-group>. <comment>SAMHSA Release. 2023 National Survey on Drug Use and Health Data [press release]. 2023</comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.samhsa.gov/data/sites/default/files/NSDUH%202023%20Annual%20Release/2023-nsduh-main-highlights.pdf" ext-link-type="uri">https://www.samhsa.gov/data/sites/default/files/NSDUH%202023%20Annual%20Release/2023-nsduh-main-highlights.pdf</ext-link>. Accessed 4 August 2024.</mixed-citation></ref><ref id="ofaf315-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bradley</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname> &#160;<given-names>EW</given-names></string-name>, <string-name name-style="western"><surname>Asher</surname> &#160;<given-names>A</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Estimated number of people who inject drugs in the United States</article-title>. <source>Clin Infect Dis</source> &#160;<year>2023</year>; <volume>76</volume>:<fpage>96</fpage>&#8211;<lpage>102</lpage>.<pub-id pub-id-type="pmid">35791261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciac543</pub-id><pub-id pub-id-type="pmcid">PMC10202436</pub-id></mixed-citation></ref><ref id="ofaf315-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McCarthy</surname> &#160;<given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Baggs</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>See</surname> &#160;<given-names>I</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Bacterial infections associated with substance use disorders, large cohort of United States hospitals, 2012-2017</article-title>. <source>Clin Infect Dis</source> &#160;<year>2020</year>; <volume>71</volume>:<fpage>e37</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">31907515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciaa008</pub-id><pub-id pub-id-type="pmcid">PMC7900878</pub-id></mixed-citation></ref><ref id="ofaf315-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marks</surname> &#160;<given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Nolan</surname> &#160;<given-names>NS</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname> &#160;<given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Durkin</surname> &#160;<given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Weimer</surname> &#160;<given-names>MB</given-names></string-name></person-group>. <article-title>Infectious complications of injection drug use</article-title>. <source>Med Clin North Am</source> &#160;<year>2022</year>; <volume>106</volume>:<fpage>187</fpage>&#8211;<lpage>200</lpage>.<pub-id pub-id-type="pmid">34823730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcna.2021.08.006</pub-id></mixed-citation></ref><ref id="ofaf315-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baddour</surname> &#160;<given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname> &#160;<given-names>WR</given-names></string-name>, <string-name name-style="western"><surname>Bayer</surname> &#160;<given-names>AS</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association</article-title>. <source>Circulation</source> &#160;<year>2015</year>; <volume>132</volume>:<fpage>1435</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">26373316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIR.0000000000000296</pub-id></mixed-citation></ref><ref id="ofaf315-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Minter</surname> &#160;<given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Appa</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chambers</surname> &#160;<given-names>HF</given-names></string-name>, <string-name name-style="western"><surname>Doernberg</surname> &#160;<given-names>SB</given-names></string-name></person-group>. <article-title>Contemporary management of Staphylococcus aureus bacteremia-controversies in clinical practice</article-title>. <source>Clin Infect Dis</source> &#160;<year>2023</year>; <volume>77</volume>:<fpage>e57</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">37950887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciad500</pub-id><pub-id pub-id-type="pmcid">PMC11959183</pub-id></mixed-citation></ref><ref id="ofaf315-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Spellberg</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Aggrey</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Brennan</surname> &#160;<given-names>MB</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Use of novel strategies to develop guidelines for management of pyogenic osteomyelitis in adults: a WikiGuidelines Group Consensus Statement</article-title>. <source>JAMA Netw Open</source> &#160;<year>2022</year>; <volume>5</volume>:<fpage>e2211321</fpage>.<pub-id pub-id-type="pmid">35536578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.11321</pub-id><pub-id pub-id-type="pmcid">PMC9092201</pub-id></mixed-citation></ref><ref id="ofaf315-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Norris</surname> &#160;<given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Shrestha</surname> &#160;<given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Allison</surname> &#160;<given-names>GM</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>2018 Infectious Diseases Society of America Clinical Practice Guideline for the management of outpatient parenteral antimicrobial therapy</article-title>. <source>Clin Infect Dis</source> &#160;<year>2018</year>; <volume>68</volume>:<fpage>e1</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciy745</pub-id><pub-id pub-id-type="pmid">30423035</pub-id></mixed-citation></ref><ref id="ofaf315-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname> &#160;<given-names>HK</given-names></string-name>, <string-name name-style="western"><surname>Rombach</surname> &#160;<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Zambellas</surname> &#160;<given-names>R</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Oral versus intravenous antibiotics for bone and joint infection</article-title>. <source>N Engl J Med</source> &#160;<year>2019</year>; <volume>380</volume>:<fpage>425</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">30699315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1710926</pub-id><pub-id pub-id-type="pmcid">PMC6522347</pub-id></mixed-citation></ref><ref id="ofaf315-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iversen</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ihlemann</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gill</surname> &#160;<given-names>SU</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Partial oral versus intravenous antibiotic treatment of endocarditis</article-title>. <source>N Engl J Med</source> &#160;<year>2019</year>; <volume>380</volume>:<fpage>415</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">30152252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1808312</pub-id></mixed-citation></ref><ref id="ofaf315-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Krsak</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Scherger</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname> &#160;<given-names>MA</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Substance use disorder-associated infections&#8217; treatment with dalbavancin enabling outpatient transition (SUDDEN OUT)&#8212;an investigator-initiated single-arm unblinded prospective cohort study</article-title>. <source>Ther Adv Infect Dis</source> &#160;<year>2024</year>; <volume>11</volume>:<fpage>20499361231223889</fpage>.<pub-id pub-id-type="pmid">38249543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/20499361231223889</pub-id><pub-id pub-id-type="pmcid">PMC10798100</pub-id></mixed-citation></ref><ref id="ofaf315-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zambrano</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Paras</surname> &#160;<given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname> &#160;<given-names>J</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Real-world dalbavancin use for serious gram-positive infections: comparing outcomes between people who use and do not use drugs</article-title>. <source>Open Forum Infect Dis</source> &#160;<year>2024</year>; <volume>11</volume>:<fpage>ofae186</fpage>.<pub-id pub-id-type="pmid">38651139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ofid/ofae186</pub-id><pub-id pub-id-type="pmcid">PMC11034951</pub-id></mixed-citation></ref><ref id="ofaf315-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morrisette</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname> &#160;<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Montague</surname> &#160;<given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Barber</surname> &#160;<given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>McQueen</surname> &#160;<given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Krsak</surname> &#160;<given-names>M</given-names></string-name></person-group>. <article-title>Long-acting lipoglycopeptides: &#8220;lineless antibiotics&#8221; for serious infections in persons who use drugs</article-title>. <source>Open Forum Infect Dis</source> &#160;<year>2019</year>; <volume>6</volume>:<fpage>ofz274</fpage>.<pub-id pub-id-type="pmid">31281868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ofid/ofz274</pub-id><pub-id pub-id-type="pmcid">PMC6602887</pub-id></mixed-citation></ref><ref id="ofaf315-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Solomon</surname> &#160;<given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Beieler</surname> &#160;<given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Levy</surname> &#160;<given-names>S</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Perspectives on the use of outpatient parenteral antibiotic therapy for people who inject drugs: results from an online survey of infectious diseases clinicians</article-title>. <source>Open Forum Infect Dis</source> &#160;<year>2023</year>; <volume>10</volume>:<fpage>ofad372</fpage>.<pub-id pub-id-type="pmid">37520410</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ofid/ofad372</pub-id><pub-id pub-id-type="pmcid">PMC10372854</pub-id></mixed-citation></ref><ref id="ofaf315-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rapoport</surname> &#160;<given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Fischer</surname> &#160;<given-names>LS</given-names></string-name>, <string-name name-style="western"><surname>Santibanez</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Beekmann</surname> &#160;<given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Polgreen</surname> &#160;<given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Rowley</surname> &#160;<given-names>CF</given-names></string-name></person-group>. <article-title>Infectious diseases physicians&#8217; perspectives regarding injection drug use and related infections, United States, 2017</article-title>. <source>Open Forum Infect Dis</source> &#160;<year>2018</year>; <volume>5</volume>:<fpage>ofy132</fpage>.<pub-id pub-id-type="pmid">30018999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ofid/ofy132</pub-id><pub-id pub-id-type="pmcid">PMC6041812</pub-id></mixed-citation></ref><ref id="ofaf315-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morales</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Smyth</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Zubiago</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bearnot</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wurcel</surname> &#160;<given-names>AG</given-names></string-name></person-group>. <article-title>&#8220;They just assume that we&#8217;re all going to do the wrong thing with it. It&#8217;s just not true&#8221;: stakeholder perspectives about peripherally inserted central catheters in people who inject drugs</article-title>. <source>Open Forum Infect Dis</source> &#160;<year>2022</year>; <volume>9</volume>:<fpage>ofac364</fpage>.<pub-id pub-id-type="pmid">36267246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ofid/ofac364</pub-id><pub-id pub-id-type="pmcid">PMC9579457</pub-id></mixed-citation></ref><ref id="ofaf315-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Suzuki</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Montgomery</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hayden</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Price</surname> &#160;<given-names>C</given-names></string-name></person-group>. <article-title>Outpatient parenteral antimicrobial therapy among people who inject drugs: a review of the literature</article-title>. <source>Open Forum Infect Dis</source> &#160;<year>2018</year>; <volume>5</volume>:<fpage>ofy194</fpage>.<pub-id pub-id-type="pmid">30211247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ofid/ofy194</pub-id><pub-id pub-id-type="pmcid">PMC6127783</pub-id></mixed-citation></ref><ref id="ofaf315-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dobson</surname> &#160;<given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Loewenthal</surname> &#160;<given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname> &#160;<given-names>K</given-names></string-name></person-group>. <article-title>Comparing injecting drug users with others receiving outpatient parenteral antibiotic therapy</article-title>. <source>Open Forum Infect Dis</source> &#160;<year>2017</year>; <volume>4</volume>:<fpage>ofx183</fpage>.<pub-id pub-id-type="pmid">29026870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ofid/ofx183</pub-id><pub-id pub-id-type="pmcid">PMC5632303</pub-id></mixed-citation></ref><ref id="ofaf315-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ho</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Archuleta</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sulaiman</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Fisher</surname> &#160;<given-names>D</given-names></string-name></person-group>. <article-title>Safe and successful treatment of intravenous drug users with a peripherally inserted central catheter in an outpatient parenteral antibiotic treatment service</article-title>. <source>J Antimicrob Chemother</source> &#160;<year>2010</year>; <volume>65</volume>:<fpage>2641</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">20864497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkq355</pub-id></mixed-citation></ref><ref id="ofaf315-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Price</surname> &#160;<given-names>CN</given-names></string-name>, <string-name name-style="western"><surname>Solomon</surname> &#160;<given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname> &#160;<given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Montgomery</surname> &#160;<given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname> &#160;<given-names>J</given-names></string-name></person-group>. <article-title>Feasibility and safety of outpatient parenteral antimicrobial therapy in conjunction with addiction treatment for people who inject drugs</article-title>. <source>J Infect Dis</source> &#160;<year>2020</year>; <volume>222</volume>(<issue>Suppl 5</issue>):<fpage>S494</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">32877541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiaa025</pub-id><pub-id pub-id-type="pmcid">PMC7566637</pub-id></mixed-citation></ref><ref id="ofaf315-B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vazirian</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jerry</surname> &#160;<given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Shrestha</surname> &#160;<given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname> &#160;<given-names>SM</given-names></string-name></person-group>. <article-title>Outcomes of outpatient parenteral antimicrobial therapy in patients with injection drug use</article-title>. <source>Psychosomatics</source> &#160;<year>2018</year>; <volume>59</volume>:<fpage>490</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">29685397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psym.2018.02.005</pub-id></mixed-citation></ref><ref id="ofaf315-B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Elixhauser</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Steiner</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Harris</surname> &#160;<given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Coffey</surname> &#160;<given-names>RM</given-names></string-name></person-group>. <article-title>Comorbidity measures for use with administrative data</article-title>. <source>Med Care</source> &#160;<year>1998</year>; <volume>36</volume>:<fpage>8</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">9431328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00005650-199801000-00004</pub-id></mixed-citation></ref><ref id="ofaf315-B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morgan</surname> &#160;<given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Barocas</surname> &#160;<given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Murphy</surname> &#160;<given-names>SM</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Comparison of rates of overdose and hospitalization after initiation of medication for opioid use disorder in the inpatient vs outpatient setting</article-title>. <source>JAMA Netw Open</source> &#160;<year>2020</year>; <volume>3</volume>:<fpage>e2029676</fpage>.<pub-id pub-id-type="pmid">33320266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2020.29676</pub-id><pub-id pub-id-type="pmcid">PMC7739119</pub-id></mixed-citation></ref><ref id="ofaf315-B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tan</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Shojaei</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Wiener</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Koivu</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Silverman</surname> &#160;<given-names>M</given-names></string-name></person-group>. <article-title>Risk of new bloodstream infections and mortality among people who inject drugs with infective endocarditis</article-title>. <source>JAMA Netw Open</source> &#160;<year>2020</year>; <volume>3</volume>:<fpage>e2012974</fpage>.<pub-id pub-id-type="pmid">32785635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2020.12974</pub-id><pub-id pub-id-type="pmcid">PMC7424403</pub-id></mixed-citation></ref><ref id="ofaf315-B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Halavaara</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Anttila</surname> &#160;<given-names>VJ</given-names></string-name>, <string-name name-style="western"><surname>J&#228;rvinen</surname> &#160;<given-names>A</given-names></string-name></person-group>. <article-title>Infective endocarditis in people who inject drugs-a 5-year follow-up: &#8220;I&#8217;ve seen the needle and the damage done&#8221;</article-title>. <source>Open Forum Infect Dis</source> &#160;<year>2025</year>; <volume>12</volume>:<fpage>ofaf057</fpage>.<pub-id pub-id-type="pmid">40242062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ofid/ofaf057</pub-id><pub-id pub-id-type="pmcid">PMC12001338</pub-id></mixed-citation></ref><ref id="ofaf315-B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>von Elm</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Altman</surname> &#160;<given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Egger</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pocock</surname> &#160;<given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>G&#248;tzsche</surname> &#160;<given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Vandenbroucke</surname> &#160;<given-names>JP</given-names></string-name></person-group>. <article-title>The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies</article-title>. <source>J Clin Epidemiol</source> &#160;<year>2008</year>; <volume>61</volume>:<fpage>344</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">18313558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinepi.2007.11.008</pub-id></mixed-citation></ref><ref id="ofaf315-B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Beieler</surname> &#160;<given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Dellit</surname> &#160;<given-names>TH</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname> &#160;<given-names>JD</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Successful implementation of outpatient parenteral antimicrobial therapy at a medical respite facility for homeless patients</article-title>. <source>J Hosp Med</source> &#160;<year>2016</year>; <volume>11</volume>:<fpage>531</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">27120700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jhm.2597</pub-id></mixed-citation></ref><ref id="ofaf315-B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eaton</surname> &#160;<given-names>EF</given-names></string-name>, <string-name name-style="western"><surname>Mathews</surname> &#160;<given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Lane</surname> &#160;<given-names>PS</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>A 9-point risk assessment for patients who inject drugs and require intravenous antibiotics: focusing inpatient resources on patients at greatest risk of ongoing drug use</article-title>. <source>Clin Infect Dis</source> &#160;<year>2019</year>; <volume>68</volume>:<fpage>1041</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="pmid">30165395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciy722</pub-id></mixed-citation></ref><ref id="ofaf315-B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Krsak</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Morrisette</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname> &#160;<given-names>M</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Advantages of outpatient treatment with long-acting lipoglycopeptides for serious gram-positive infections: a review</article-title>. <source>Pharmacotherapy</source> &#160;<year>2020</year>; <volume>40</volume>:<fpage>469</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">32239771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/phar.2389</pub-id></mixed-citation></ref><ref id="ofaf315-B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ho</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Archuleta</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tice</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fisher</surname> &#160;<given-names>D</given-names></string-name></person-group>. <article-title>International approaches to treating intravenous drug users in outpatient parenteral antibiotic services</article-title>. <source>Inf Dis Clin Pract</source> &#160;<year>2012</year>; <volume>20</volume>:<fpage>192</fpage>&#8211;<lpage>5</lpage>.</mixed-citation></ref><ref id="ofaf315-B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fanucchi</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Leedy</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Li</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Thornton</surname> &#160;<given-names>AC</given-names></string-name></person-group>. <article-title>Perceptions and practices of physicians regarding outpatient parenteral antibiotic therapy in persons who inject drugs</article-title>. <source>J Hosp Med</source> &#160;<year>2016</year>; <volume>11</volume>:<fpage>581</fpage>&#8211;<lpage>2</lpage>.<pub-id pub-id-type="pmid">27043146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jhm.2582</pub-id></mixed-citation></ref><ref id="ofaf315-B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Garland</surname> &#160;<given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Froeliger</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zeidan</surname> &#160;<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Partin</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Howard</surname> &#160;<given-names>MO</given-names></string-name></person-group>. <article-title>The downward spiral of chronic pain, prescription opioid misuse, and addiction: cognitive, affective, and neuropsychopharmacologic pathways</article-title>. <source>Neurosci Biobehav Rev</source> &#160;<year>2013</year>; <volume>37</volume>(<issue>10 Pt 2</issue>):<fpage>2597</fpage>&#8211;<lpage>607</lpage>.<pub-id pub-id-type="pmid">23988582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2013.08.006</pub-id><pub-id pub-id-type="pmcid">PMC3967721</pub-id></mixed-citation></ref><ref id="ofaf315-B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Magidson</surname> &#160;<given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname> &#160;<given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Lejuez</surname> &#160;<given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Blanco</surname> &#160;<given-names>C</given-names></string-name></person-group>. <article-title>Comparison of the course of substance use disorders among individuals with and without generalized anxiety disorder in a nationally representative sample</article-title>. <source>J Psychiatr Res</source> &#160;<year>2012</year>; <volume>46</volume>:<fpage>659</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="pmid">22444600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpsychires.2012.02.011</pub-id><pub-id pub-id-type="pmcid">PMC3334401</pub-id></mixed-citation></ref><ref id="ofaf315-B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Torrens</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gilchrist</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Domingo-Salvany</surname> &#160;<given-names>A</given-names></string-name></person-group>. <article-title>Psychiatric comorbidity in illicit drug users: substance-induced versus independent disorders</article-title>. <source>Drug Alcohol Depend</source> &#160;<year>2011</year>; <volume>113</volume>:<fpage>147</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">20801586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2010.07.013</pub-id></mixed-citation></ref><ref id="ofaf315-B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wolitzky-Taylor</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Operskalski</surname> &#160;<given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Ries</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Craske</surname> &#160;<given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Roy-Byrne</surname> &#160;<given-names>P</given-names></string-name></person-group>. <article-title>Understanding and treating comorbid anxiety disorders in substance users: review and future directions</article-title>. <source>J Addict Med</source> &#160;<year>2011</year>; <volume>5</volume>:<fpage>233</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">22042216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ADM.0b013e31823276d7</pub-id></mixed-citation></ref><ref id="ofaf315-B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Magura</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rosenblum</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fong</surname> &#160;<given-names>C</given-names></string-name></person-group>. <article-title>Factors associated with medication adherence among psychiatric outpatients at substance abuse risk</article-title>. <source>Open Addict J</source> &#160;<year>2011</year>; <volume>4</volume>:<fpage>58</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">23264842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1874941001104010058</pub-id><pub-id pub-id-type="pmcid">PMC3526017</pub-id></mixed-citation></ref><ref id="ofaf315-B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gryczynski</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schwartz</surname> &#160;<given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>O'Grady</surname> &#160;<given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Restivo</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname> &#160;<given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Jaffe</surname> &#160;<given-names>JH</given-names></string-name></person-group>. <article-title>Understanding patterns of high-cost health care use across different substance user groups</article-title>. <source>Health Aff (Millwood)</source> &#160;<year>2016</year>; <volume>35</volume>:<fpage>12</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26733696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1377/hlthaff.2015.0618</pub-id><pub-id pub-id-type="pmcid">PMC4936480</pub-id></mixed-citation></ref><ref id="ofaf315-B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fanucchi</surname> &#160;<given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Murphy</surname> &#160;<given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Surratt</surname> &#160;<given-names>H</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Design and protocol of the buprenorphine plus outpatient parenteral antimicrobial therapy (B-OPAT) study: a randomized clinical trial of integrated outpatient treatment of opioid use disorder and severe, injection-related infections</article-title>. <source>Ther Adv Infect Dis</source> &#160;<year>2022</year>; <volume>9</volume>:<fpage>20499361221108005</fpage>.<pub-id pub-id-type="pmid">35847566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/20499361221108005</pub-id><pub-id pub-id-type="pmcid">PMC9277431</pub-id></mixed-citation></ref><ref id="ofaf315-B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jawa</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rozansky</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Clemens</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fagan</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Walley</surname> &#160;<given-names>AY</given-names></string-name></person-group>. <article-title>Rethinking home-based outpatient parenteral antibiotic therapy for persons who inject drugs: an opportunity for change in the time of COVID-19</article-title>. <source>J Addict Med</source> &#160;<year>2022</year>; <volume>16</volume>:<fpage>e70</fpage>&#8211;<lpage>2</lpage>.<pub-id pub-id-type="pmid">33870955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ADM.0000000000000856</pub-id><pub-id pub-id-type="pmcid">PMC8501142</pub-id></mixed-citation></ref><ref id="ofaf315-B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gelman</surname> &#160;<given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Stenehjem</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Foster</surname> &#160;<given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Tinker</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Grisel</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Webb</surname> &#160;<given-names>BJ</given-names></string-name></person-group>. <article-title>A novel program to provide drug recovery assistance and outpatient parenteral antibiotic therapy in people who inject drugs</article-title>. <source>Open Forum Infect Dis</source> &#160;<year>2022</year>; <volume>9</volume>:<fpage>ofab629</fpage>.<pub-id pub-id-type="pmid">35106314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ofid/ofab629</pub-id><pub-id pub-id-type="pmcid">PMC8801220</pub-id></mixed-citation></ref><ref id="ofaf315-B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fanucchi</surname> &#160;<given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Walsh</surname> &#160;<given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Thornton</surname> &#160;<given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Lofwall</surname> &#160;<given-names>MR</given-names></string-name></person-group>. <article-title>Integrated outpatient treatment of opioid use disorder and injection-related infections: a description of a new care model</article-title>. <source>Prev Med</source> &#160;<year>2019</year>; <volume>128</volume>:<fpage>105760</fpage>.<pub-id pub-id-type="pmid">31251946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ypmed.2019.105760</pub-id></mixed-citation></ref><ref id="ofaf315-B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fanucchi</surname> &#160;<given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Walsh</surname> &#160;<given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Thornton</surname> &#160;<given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Nuzzo</surname> &#160;<given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Lofwall</surname> &#160;<given-names>MR</given-names></string-name></person-group>. <article-title>Outpatient parenteral antimicrobial therapy plus buprenorphine for opioid use disorder and severe injection-related infections</article-title>. <source>Clin Infect Dis</source> &#160;<year>2020</year>; <volume>70</volume>:<fpage>1226</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">31342057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciz654</pub-id><pub-id pub-id-type="pmcid">PMC7931831</pub-id></mixed-citation></ref><ref id="ofaf315-B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Barocas</surname> &#160;<given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Morgan</surname> &#160;<given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>McLoone</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wurcel</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname> &#160;<given-names>MD</given-names></string-name></person-group>. <article-title>Outcomes associated with medications for opioid use disorder among persons hospitalized for infective endocarditis</article-title>. <source>Clin Infect Dis</source> &#160;<year>2021</year>; <volume>72</volume>:<fpage>472</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">31960025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciaa062</pub-id><pub-id pub-id-type="pmcid">PMC7850516</pub-id></mixed-citation></ref><ref id="ofaf315-B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wakeman</surname> &#160;<given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Rich</surname> &#160;<given-names>JD</given-names></string-name></person-group>. <article-title>Barriers to post-acute care for patients on opioid agonist therapy; an example of systematic stigmatization of addiction</article-title>. <source>J Gen Intern Med</source> &#160;<year>2017</year>; <volume>32</volume>:<fpage>17</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">27393486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11606-016-3799-7</pub-id><pub-id pub-id-type="pmcid">PMC5215148</pub-id></mixed-citation></ref><ref id="ofaf315-B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McDonald</surname> &#160;<given-names>EG</given-names></string-name>, <string-name name-style="western"><surname>Aggrey</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Tar&#305;k Aslan</surname> &#160;<given-names>A</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Guidelines for diagnosis and management of infective endocarditis in adults: a wiki guidelines group consensus statement</article-title>. <source>JAMA Netw Open</source> &#160;<year>2023</year>; <volume>6</volume>:<fpage>e2326366</fpage>.<pub-id pub-id-type="pmid">37523190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2023.26366</pub-id></mixed-citation></ref><ref id="ofaf315-B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Veve</surname> &#160;<given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname> &#160;<given-names>ZA</given-names></string-name>, <string-name name-style="western"><surname>Yeager</surname> &#160;<given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Wright</surname> &#160;<given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Shorman</surname> &#160;<given-names>MA</given-names></string-name></person-group>. <article-title>Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections</article-title>. <source>Int J Antimicrob Agents</source> &#160;<year>2020</year>; <volume>56</volume>:<fpage>106210</fpage>.<pub-id pub-id-type="pmid">33223119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2020.106210</pub-id></mixed-citation></ref><ref id="ofaf315-B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dickson-Gomez</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Weeks</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Green</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Boutouis</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Galletly</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Christenson</surname> &#160;<given-names>E</given-names></string-name></person-group>. <article-title>Insurance barriers to substance use disorder treatment after passage of mental health and addiction parity laws and the affordable care act: a qualitative analysis</article-title>. <source>Drug Alcohol Depend Rep</source> &#160;<year>2022</year>; <volume>3</volume>:<fpage>100051</fpage>.<pub-id pub-id-type="pmid">36845978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dadr.2022.100051</pub-id><pub-id pub-id-type="pmcid">PMC9948907</pub-id></mixed-citation></ref><ref id="ofaf315-B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marks</surname> &#160;<given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Nolan</surname> &#160;<given-names>NS</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Muthulingam</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname> &#160;<given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Durkin</surname> &#160;<given-names>MJ</given-names></string-name></person-group>. <article-title>Use of ICD-10 codes for identification of injection drug use-associated infective endocarditis is nonspecific and obscures critical findings on impact of medications for opioid use disorder</article-title>. <source>Open Forum Infect Dis</source> &#160;<year>2020</year>; <volume>7</volume>:<fpage>ofaa414</fpage>.<pub-id pub-id-type="pmid">33094117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ofid/ofaa414</pub-id><pub-id pub-id-type="pmcid">PMC7566393</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>